OVA inudced asthma models

Autoimmune Nephropathy Models and Efficacy Services
IgA NephropathyC3 GlomerulonephritisLupus NephritisMembranous Nphropathy
Asthma Models and Efficacy Services
HDM induced asthma modelsOVA inudced asthma models
Systemic Lupus Erythematosus (SLE) Models and Efficacy Services
Spontaneous SLE ModelsInduction SLE ModelsImmune Reconstitution SLE Models
Sjögren's Syndrome Models and Efficacy Services
Salivary Gland Protein Induced Sjögren's Syndrome Mouse ModelSTING Agonist Induced Sjögren’s Syndrome Mouse Model
Neuroimmune Diseases Models and Efficacy Services
Multiple Sclerosis (MS) ModelsMyasthenia Gravis (MG) Models
Autoimmune Dermatoses Models and Efficacy Services
Psoriasis ModelsAtopic DermatitisAlopecia Areata (AA)Vitiligo ModelsSclerodermaUrticaria
Inflammatory Bowel Disease (IBD) Models and Efficacy Services
DSS Induced IBD ModelAdaptive T cell Transfer IBD ModelImmune Reconstitution IBD ModelAnti-CD40 Induced Colitis Models
Rheumatoid Arthritis (RA) Models and Efficacy Services
Collagen Induced Arthritis ModelCollagen Antibody Induced Arthritis ModelImmune Reconstitution Arthritis ModelmBSA induced Induced DTHA Model
Immune Reconstitution Autoimmune Disease Models and Efficacy Services
SLEIBDArthritisMyasthenia GravisPassive Cutaneous AnaphylaxisPassive Systemic Anaphylaxis (PSA)

Model establishment


  • Experimental mouse strains: BALB/c, male

  • Modeling reagent: OVA

  • Dosing route: intratracheal instillation


1.jpeg


Efficacy study: Dexamethasone (DXMS) 

 

  • Serum IgG1, total IgE, OVA-sIgG and OVA-sIgE


2.jpeg

Serum levels of IgG1, total IgE, OVA-sIgG and OVA-sIgE were elevated in the OVA-induced asthma mouse model group but decreased in G3 following treatment with dexamethasone (DXMS). G1: vehicle control; G2: OVA + vehicle; G3: OVA + DXMS. Data is expressed as Mean ± SEM. Statistical analysis was performed using one-way ANOVA. P<0.05; **: P<0.01; ***: P<0.001; ****: P<0.0001.

 

  • Cytokines analysis


3.jpeg

Levels of IL-5 in bronchoalveolar lavage fluid (BALF) increased after OVA-induction and decreased in the DXMS treated group G3. Tissue levels of IL-33, IL-4, IL-5, IL-6, IL-13, IL-1β, IFN-γ and TNF-α increased significantly after OVA induction. Treatment with DXMS decreased tissue levels of IL-33, IL-4, IL-5, IL-6, IL-13, IL-1β and IFN-γ but not TNF-α. G1: vehicle control; G2: OVA + vehicle; G3: OVA + DXMS. Data is expressed as Mean ± SEM. Statistical analysis was performed using one-way ANOVA. P<0.05; **: P<0.01. 


  • Histopathology


4.jpeg

HE Staining. Inflammatory cells were showed by black arrows. Bar=100 μm in the top row. Bar=20 μm in the bottom row. Toluidine Blue Staining. Compared to G1, G2 showed moderate to massive infiltration of inflammatory cells including eosinophils, mast cells, lymphocytes, macrophages, and neutrophils surrounding the airways and vessels of the lungs. Compared to G2, G3 showed significantly reduced inflammatory cell infiltration surrounding the airways and blood vessels.


Mast cell degranulation are indicated by red arrows. Bar=100 μm in the top row. Bar=20 μm in the bottom row. Compared to G1, G2 showed occasional degranulation of mast cells in the interstitium of the lungs. Compared to G2, G3 showed rare mast cell degranulation in the interstitium of the lungs.


PAS Staining. Mucus attachment was shown by blue arrows. Bar=100 μm in the top row. Bar=20 μm in the bottom row. Compared to G1, G2 showed moderate to abundant PAS-positive mucous material in the bronchi or bronchiolar mucosal epithelium. Compared to G2, G3 showed only occasional PAS-positive mucous material in the mucosal epithelium of the bronchi or bronchioles.

 

Efficacy study: Anti-human CD69 antibody


  • Experimental mouse strains: BALB/c-hCD69 mice, both male and female

  • Modeling reagent: OVA

  • Dosing route: intratracheal instillation


5.jpeg

6.jpeg

OVA-induced asthma resulted in an increase of lung IL-4, IL-6, IL-33, IL17A, and TNF-α mRNA levels. Administration of anti-CD69 antibody resulted in a decrease in lung IL-4 mRNA levels. No statistically significant decrease in IL-6, IL-33, IL17A, mRNA levels was observed with anti-CD69 antibody administration.


Lung HE score and airway wall thickness increased after OVA induction. No statistically significant decrease in airway wall thickness was observed with anti-CD69 antibody administration. Notes: Mucosal epithelial thickening (blue arrow), eosinophils (orange arrow), inflammatory cell infiltration (green arrow), necrotic lesion (black arrow), lymphocytes (yellow arrow); The first row: Bar=200μm; Second row: Bar=50μm.

Data is expressed as Mean ± SEM. Statistical analysis was performed using one-way ANOVA. **: P<0.01; ***: P<0.001.


TALK WITH OUR EXPERTS

GemPharmatech is committed to protecting and respecting your privacy, and we'll only use your personal information to administer your account and to provide the products and services you requested from us. From time to time, we would like to contact you about our products and services, as well as other content that may be of interest to you. If you consent to us contacting you for this purpose, please click below to say how you would like us to contact you:

In order to provide you with the content requested, we need to store and process your personal data. If you consent to us storing your personal data for this purpose, please click the checkbox below.

You can unsubscribe from these communications at any time. For more information on how to unsubscribe, our privacy practices, and how we are committed to protecting and respecting your privacy, please review our Privacy Policy.